M&A
AVS Bio acquires Cambridge life sciences firm Biorbyt
September 29, 2026
Biotech
M&A
Key Facts
Signal Type
M&A
Industry
Biotech
Companies
AVS Bio, Biorbyt, Arlington Capital Partners
Date
September 29, 2026
AVS Bio, a leading global provider of biological materials and services headquartered in Norwich, CT, has acquired Biorbyt, a Cambridge, UK-based supplier of bio-reagents, antibodies, proteins, and other biomaterials. Biorbyt brings a catalog of over 1 million SKUs and a sophisticated ecommerce platform serving a global customer base of pharmaceutical, biotech, and academic institutions. The acquisition is backed by Arlington Capital Partners, which has a track record of building leading companies in highly regulated industries.
AVS Bio's existing customers and Biorbyt's global customer base will see an expanded product catalog and improved digital commerce capabilities. The combined entity now operates over 20 facilities across North America and Europe, with a broader reach into pharma, biotech, and academia. For vendors selling into the life sciences supply chain, AVS Bio becomes a larger, more complex account requiring integrated systems for inventory, order management, and customer relationship management.
Monitor AVS Bio's integration of Biorbyt's ecommerce platform and catalog into its existing operations. This will likely involve system consolidation, data migration, and process standardization, creating needs for ERP, CRM, and supply-chain software. Additionally, watch for further acquisitions as Arlington Capital continues to scale the platform, which may open new vendor opportunities across the life sciences value chain.
Source:
Business WeeklyGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
